about
Co-crystal structures of inhibitors with MRCKβ, a key regulator of tumor cell invasionActomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyperplasia and tumor growthRho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapyHow apoptotic cells aid in the removal of their own cold dead bodiesAnalysis of the human cofilin 1 structure reveals conformational changes required for actin bindingRas signalling is required for inactivation of the tumour suppressor pRb cell-cycle control proteinLIM kinases: function, regulation and association with human diseaseBlebs produced by actin-myosin contraction during apoptosis release damage-associated molecular pattern proteins before secondary necrosis occursConditional ROCK activation in vivo induces tumor cell dissemination and angiogenesisExtracellular ATP causes ROCK I-dependent bleb formation in P2X7-transfected HEK293 cellsAP-1 differentially expressed proteins Krp1 and fibronectin cooperatively enhance Rho-ROCK-independent mesenchymal invasion by altering the function, localization, and activity of nondifferentially expressed proteins.Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53K-Ras mediated murine epidermal tumorigenesis is dependent upon and associated with elevated Rac1 activityMembrane blebbing during apoptosis results from caspase-mediated activation of ROCK I.Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions.Development of a high-throughput screening method for LIM kinase 1 using a luciferase-based assay of ATP consumption.LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells.Mammary stem cells have myoepithelial cell propertiesRho GTPase signalling pathways in the morphological changes associated with apoptosis.Gem GTPase: between a ROCK and a hard place.Dispatch. GTPase signalling: new functions for Diaphanous-related formins.A novel small-molecule MRCK inhibitor blocks cancer cell invasionContraction reaction: mechanical regulation of Rho GTPase.RAS and RHO GTPases in G1-phase cell-cycle regulation.Targeting Ras and Rho GTPases as opportunities for cancer therapeutics.Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis.Actin-myosin-based contraction is responsible for apoptotic nuclear disintegrationLIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation.Applications for ROCK kinase inhibitionThe ras signalling pathway as a target in cancer therapy.The actin cytoskeleton in cancer cell motility.Constitutively active RhoA inhibits proliferation by retarding G(1) to S phase cell cycle progression and impairing cytokinesis.ROCK signalling induced gene expression changes in mouse pancreatic ductal adenocarcinoma cells.Reduced LIMK2 expression in colorectal cancer reflects its role in limiting stem cell proliferation.The actin-myosin regulatory MRCK kinases: regulation, biological functions and associations with human cancer.ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth.Targeting Rho GTPase signaling for cancer therapy.SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradationPolarized cell motility induces hydrogen peroxide to inhibit cofilin via cysteine oxidation.
P50
Q24338744-8A2437E2-4E12-4374-9A95-2DF1151AD574Q24613142-4347E54B-B6DA-4FE0-87A3-FECD625199A6Q24631326-0CB6E175-1DD8-4144-B418-487088B9770CQ27026126-7099AD9D-FB40-4AD4-83B0-6AEB0CE1367AQ27679856-B2A32D19-E21A-4A14-8E65-FABA6E0662ECQ28256250-7FCD60AF-5EAB-4E0C-B2F7-4B82224D3C8AQ28287736-6A432155-F853-4AA9-90B4-2E8693B9A8AEQ28293202-C5FEA43A-038C-4176-B2A8-78220CF401A8Q28298687-33DD86FD-BC04-4CFD-9F98-13E92900B125Q28565083-81C563CF-6011-4D45-A411-92F18FFB8E8BQ30159929-9DDE5ADB-B1D4-4DAF-A28F-39148A567FC5Q30498093-6BB34FCB-2FA9-4FC7-8FDA-4710A53CC71AQ33831720-53C7F0C0-DF90-4AB7-822F-99A4CAED3307Q33941102-6F12F75B-DBF7-4F52-A00F-BCC3486D65AAQ33968841-B03D4FBE-2403-48B4-8128-6313BFC86BDEQ34095992-7A2DA809-7351-4468-9FE2-F536AC945E93Q34191636-1399F18C-CF97-4342-BA19-2B1F3D4A807DQ34282358-905B6396-6D06-4A0B-B607-975F27909052Q34612747-1C6D87DB-D02C-46F7-9E4D-CB71FC47C340Q34784724-5B75C888-04D6-4D38-BE84-3E7F8DDB8801Q35119289-80A9D60F-4CF4-4223-9C1E-A8BF659344EBQ35307266-4A07E017-D17E-49FA-B365-C1447F61BF70Q35727106-AB1BF8C4-2DF6-4B74-A1CC-AF8EF0206024Q35762468-8B212B57-57BC-4BC8-BF6A-75207F536CE7Q36015529-7ACC163B-4F28-4F7A-BD0B-3C5DC0D29C37Q36190681-DFA441BE-B111-4430-B60E-70AFB6CD5D2EQ36321103-24A87977-3D3A-4B94-9991-24394465C9F5Q36629339-5FB78E40-4DE6-4111-A0A6-E1EA07D3BBDBQ36649417-FEC84D87-8D1A-45DE-8B95-A4DD58077E78Q36868875-2938D945-2E69-4E39-8E8B-D3EDFCD9A5CDQ37170851-F9CB0760-2F4F-44F3-B849-E410F4131FF9Q37361297-C68696B0-1A30-4965-BEB9-7ECA9AA8F593Q37401278-2F348856-66CB-4211-8437-832150F949E2Q37600049-D8E9E4AF-DA54-4BCE-A76A-93D87DD915BAQ37614505-673E05C7-5016-4EB5-9D95-BDAFC2479DD3Q37618014-24ECCE67-F2AF-4F1B-B987-0F2A0BC2DA8FQ37984123-FE4E87ED-1568-4858-B239-6647E6A2362FQ38337665-45DD3BF2-B420-4C76-9A87-C8E8DB597ECBQ38355051-5B76F50B-D200-4DB9-8AF2-1E74E0EFDA46Q38874002-AEB94C35-3747-456B-88E2-76A6A0079453
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael F Olson
@es
Michael F Olson
@nl
Michael F Olson
@sl
Michael F. Olson
@en
type
label
Michael F Olson
@es
Michael F Olson
@nl
Michael F Olson
@sl
Michael F. Olson
@en
prefLabel
Michael F Olson
@es
Michael F Olson
@nl
Michael F Olson
@sl
Michael F. Olson
@en
P106
P1153
7402052835
P21
P31
P496
0000-0003-3428-3507